How Is The Market Feeling About Regeneron Pharmaceuticals Inc?
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 4.85% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 2.16% of all regular shares that are available for trading.
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.
Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies…
ViGeneron Signed Gene Therapy Strategic Collaboration and Option Agreement With Regeneron for One Inherited Retinal Disease Target
ViGeneron GmbH, a next-generation gene therapy company, today announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron's novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).
Executives Sell More Than $262M Of 5 Stocks
Although gold futures traded higher on Monday, there were a few notable insider trades.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in…